Filtered By:
Condition: Diabetes
Countries: Canada Health
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 188 results found since Jan 2013.
Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: IL-37 Could be Beneficial
Publication date: Available online 31 January 2018 Source:Canadian Journal of Diabetes Author(s): Pio Conti, Gianpaolo Ronconi, Spyridon K. Kritas, Alessandro Caraffa, Theoharis C. Theoharides Mast cells (MCs) promote guest immune response against parasites and play a critical role in allergic and inflammatory reactions. Once they have been activated, MCs release high inflammatory compounds that can provoke serious pathological signs that can even lead to death. MCs generate a number of pre-formed, de novo synthesized compounds, and inflammatory cytokine/chemokine synthesis in response to the high affinity (Kd=10-10 M) Ig...
Source: Canadian Journal of Diabetes - February 28, 2018 Category: Endocrinology Source Type: research
The potential impact of new stent platforms for coronary revascularization in diabetics
Publication date: Available online 1 March 2018 Source:Canadian Journal of Cardiology Author(s): Gustavo S. Guandalini, Sripal Bangalore Coronary artery disease in patients with diabetes mellitus (DM) is characterized by extensive atherosclerosis, longer lesions and diffuse distal disease. Consequently, these patients have worse outcomes following coronary revascularization, regardless of the modality employed. Traditionally, coronary artery bypass grafting (CABG) has been regarded as more effective than percutaneous coronary intervention (PCI) in patients with DM, owing likely to more complete revascularization and prote...
Source: Canadian Journal of Cardiology - March 2, 2018 Category: Cardiology Source Type: research
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus
Publication date: April 2018 Source:Canadian Journal of Diabetes, Volume 42, Issue 2 Author(s): Martin H. Strauss, Alistair S. Hall The renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's also red...
Source: Canadian Journal of Diabetes - March 28, 2018 Category: Endocrinology Source Type: research
Blood Pressure –Lowering Targets in Patients With Diabetes Mellitus
Publication date: May 2018 Source:Canadian Journal of Cardiology, Volume 34, Issue 5 Author(s): Alexander A. Leung, Raj S. Padwal Diabetes is a highly prevalent medical condition that commonly coexists with hypertension. The presence of diabetes and hypertension significantly increases the risk of adverse cardiovascular events. Although compelling evidence exists from randomized controlled trials demonstrating that blood pressure (BP) reduction effectively prevents cardiovascular complications, optimal BP targets remain uncertain and continue to be the subject of ongoing controversy. Until recently, most major clinical pr...
Source: Canadian Journal of Cardiology - May 4, 2018 Category: Cardiology Source Type: research
The Potential Effects of New Stent Platforms for Coronary Revascularization in Patients With Diabetes
Publication date: May 2018 Source:Canadian Journal of Cardiology, Volume 34, Issue 5 Author(s): Gustavo S. Guandalini, Sripal Bangalore Coronary artery disease in patients with diabetes mellitus (DM) is characterized by extensive atherosclerosis, longer lesions, and diffuse distal disease. Consequently, these patients have worse outcomes after coronary revascularization, regardless of the modality used. Traditionally, coronary artery bypass grafting (CABG) has been regarded as more effective than percutaneous coronary intervention (PCI) in patients with DM, likely because of more complete revascularization and protection ...
Source: Canadian Journal of Cardiology - May 4, 2018 Category: Cardiology Source Type: research
Applicability of the Systolic Blood Pressure Intervention Trial (SPRINT) to the Canadian Population
Conclusions If fully implemented, intensive systolic BP lowering to < 120 mm Hg in SPRINT-eligible high-risk individuals would substantially increase the proportion of Canadian adults receiving BP treatment initiation or intensification.
Source: Canadian Journal of Cardiology - May 4, 2018 Category: Cardiology Source Type: research
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus
Publication date: April 2018Source: Canadian Journal of Diabetes, Volume 42, Issue 2Author(s): Martin H. Strauss, Alistair S. HallAbstractThe renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's als...
Source: Canadian Journal of Diabetes - July 5, 2018 Category: Endocrinology Source Type: research
Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could be Beneficial
Publication date: Available online 31 January 2018Source: Canadian Journal of DiabetesAuthor(s): Pio Conti, Gianpaolo Ronconi, Spyridon K. Kritas, Alessandro Caraffa, Theoharis C. TheoharidesAbstractMast cells (MCs) promote guest immune responses to parasites and play a critical role in allergic and inflammatory reactions. Once they have been activated, MCs release highly inflammatory compounds that can provoke serious pathologic signs that can lead to death. MCs generate a number of preformed, de novo synthesized compounds and inflammatory cytokine/chemokine synthesis in response to the high-affinity (Kd=10–10 M) immuno...
Source: Canadian Journal of Diabetes - July 5, 2018 Category: Endocrinology Source Type: research
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus
Publication date: April 2018Source: Canadian Journal of Diabetes, Volume 42, Issue 2Author(s): Martin H. Strauss, Alistair S. HallAbstractThe renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's als...
Source: Canadian Journal of Diabetes - July 10, 2018 Category: Endocrinology Source Type: research
Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could be Beneficial
Publication date: Available online 31 January 2018Source: Canadian Journal of DiabetesAuthor(s): Pio Conti, Gianpaolo Ronconi, Spyridon K. Kritas, Alessandro Caraffa, Theoharis C. TheoharidesAbstractMast cells (MCs) promote guest immune responses to parasites and play a critical role in allergic and inflammatory reactions. Once they have been activated, MCs release highly inflammatory compounds that can provoke serious pathologic signs that can lead to death. MCs generate a number of preformed, de novo synthesized compounds and inflammatory cytokine/chemokine synthesis in response to the high-affinity (Kd=10–10 M) immuno...
Source: Canadian Journal of Diabetes - July 10, 2018 Category: Endocrinology Source Type: research
Descriptive analysis of pharmacy services provided after community pharmacy screening
Conclusions Approximately one-third of participants received a pharmacy service within 3 months post-screening. Relatively large numbers of annual and follow-up medication reviews were delivered despite low eligibility for annual-only reviews and despite many missed opportunities for pharmacy service provision in at-risk patients. In-pharmacy screening may facilitate provision of some services, namely medication reviews, by providing opportunities to identify patients at-risk.
Source: International Journal of Clinical Pharmacy - November 26, 2018 Category: Drugs & Pharmacology Source Type: research
Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: An umbrella review
ConclusionsExtended DAPT may reduce the risk of MI and stent thrombosis but increase major bleeding and death. Whether the effects of extended DAPT are consistent across patient subgroups is unclear, and future SRs should address this knowledge gap. PROSPERO: CRD42016047735.
Source: Canadian Journal of Cardiology - February 6, 2019 Category: Cardiology Source Type: research
Atorvastatin in the treatment of lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial
Lithium is the gold-standard treatment for bipolar disorder, is highly effective in major depressive disorder, and is being investigated for therapeutic benefits in dementia, stroke, and even cancer. Approximately 350,000 Canadians use lithium and more could benefit. Despite this, clinicians are avoiding lithium, largely due to fear of renal toxicity, including irreversible chronic kidney disease (CKD). Nephrogenic Diabetes Insipidus (NDI) occurs in 20% of lithium users and independently predicts a 2-3 times increased risk of CKD.
Source: The American Journal of Geriatric Psychiatry - February 28, 2019 Category: Geriatrics Authors: Jocelyn Fotso Soh, Gabriela Torres-Platas, Serge Beaulieu, Outi Mantere, Robert Platt, Istvan Mucsi, Sybille Saury, Suzane Renaud, Andrea Levinson, Ana Andreazza, Benoit Mulsant, Daniel Mueller, Ayal Schaffer, Annemiek Dols, Nancy Low, Pablo Cervantes, Na Tags: Poster Number: EI - 48 Source Type: research
Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study
Publication date: Available online 27 March 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Ravi Retnakaran, Baiju R ShahSummaryBackgroundIn studies to date, gestational diabetes has consistently been associated with an increased future risk of cardiovascular disease, irrespective of the antepartum screening protocol or diagnostic criteria by which gestational diabetes is diagnosed. We reasoned that the resultant heterogeneity in the severity of dysglycaemia in women with gestational diabetes suggests that the relationship between gestational glycaemia and subsequent cardiovascular disease probably extends into t...
Source: The Lancet Diabetes and Endocrinology - March 28, 2019 Category: Endocrinology Source Type: research
Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier
We examined a possible protective effect of OX-A against LPS-induced ROS formation and microglia activation. To mimic in vitro the connection between gut and brain and to study the putative effect on the cortical microglia, we used a co-culture of Caco-2 cells and primary cortical microglia with Caco-2 cells placed at the apical side of a transwell and primary cortical microglia at the basolateral side. All treatments used to study the apical vs. basal connection were applied to the apical compartment. We used DHR (10 μM, 20 min), a cell-permeable fluorogenic probe useful for the detection of ROS formation, to dete...
Source: Frontiers in Endocrinology - April 9, 2019 Category: Endocrinology Source Type: research
